001351 Flucelvax Ad Layouts for Vital Catalogues_VMS 1200 px x 300 px _v3_01-FAÔÇôB.jpg

Influenza is ready to attack. Help prevent it with Flucelvax Quad.

 

Flucelvax Quad is indicated for the prevention of Influenza Virus caused by Influenza Types A and B. The vaccine is indicated for use in children and adults over the age of 2. 

 

FLUCELVAX-QUAD-2022-Feb---Pack-MOCK-UP-RGB-Right.jpg

Important Information About Flucelvax Quad

Active Ingredient 

This vaccine contains the active ingredient influenza virus haemagglutinin.

Strengthen Immunity

Flucelvax Quad works by exposing your body to the four types of Influenza virus, causing it to produce antibodies in order to fight Influenza virus. 

Single-Dose Series

Flucelvax Quad is given in a single dose series once a year.

Non-Live Vaccine 

This vaccine is a non-live vaccine and is not contraindicated in immunocompromised individuals. Risks and benefits should be carefully considered before the vaccine is administered to immunocompromised patients.  

 

Reference Materials

Frequently Asked Questions

 

PBS Information: This product is not listed on the National Immunisation Program (NIP) or the PBS.

Before prescribing, please review Product Information available at www.seqirus.com.au/products

MINIMUM PRODUCT INFORMATION Flucelvax® Quad (Inactivated Quadrivalent Influenza Vaccine (prepared in cell cultures)) - Suspension for injection. Indication: For the prevention of influenza caused by Influenza Virus, Types A and B contained in the vaccine, for use in adults and children 2 years of age and older. Contraindications: Individuals with known severe allergic reactions (e.g. anaphylaxis) to any component of the vaccine or to a previous dose of any influenza vaccine. Precautions: Treatment and supervision for anaphylactic reactions should be available. Antibody response in immunocompromised patients may be lower. Careful consideration for use in history of Guillain-Barré syndrome within 6 weeks of previous influenza vaccination. Postpone immunisation in patients with febrile illness or acute infection. A protective immune response may not be elicited in all vaccine recipients. Use in Pregnancy (Category B1): The safety of Flucelvax® Quad in pregnancy has not been assessed in clinical trials. There are no reproductive and developmental toxicity studies with Flucelvax® Quad. Reproductive and developmental toxicity data from cell-based trivalent influenza vaccine (TIVc) do not predict an increased risk of developmental abnormalities. Use in Lactation: Not been evaluated in nursing mothers. Interactions: No data available on co-administration with other vaccines. Based on clinical experience with TIVc, Flucelvax® Quad can be given at the same time as other vaccines (in separate limbs) (adverse reactions may be intensified). Adverse Effects: Local - pain, erythema. Systemic - headache, fatigue, irritability (children 2-6 years), upper respiratory tract infection, nasopharyngitis (See full PI). Dosage and Administration: Intramuscular injection only: single 0.5mL dose (children <9 years may require 2 doses - see full PI). Presentation: 0.5mL single-use syringe. Storage: Store at 2°C to 8°C; must not be frozen; protect from light. Based on Approved Product Information.

 

Are you interested in Flucelvax Quad?

You must be logged in to submit this form. If you are logged in and still cannot post, make sure "Do not track" in your browser settings is disabled.